Breastfeeding promotion and protection in Kazakhstan and Russia

Ústav hygieny 3. LF UKDepartment of Hygiene 3FM CU3. lékařská fakultaThird Faculty of Medicin

Analysis of consequences of the relationship between man, nature and technology in the context of technogenesis intellectualization

The paper presents the results of the analysis of demographic and medico-social data characterizing the dynamics of morbidity and mortality from environmental diseases, in particular, diseases of the cardiovascular system. The trend of negative natural population growth was revealed, amounting to -6.9 per 1,000 persons by 2019. The number of patients with cardiovascular diseases was 13 817,4 persons, with the overwhelming majority of the working-age population (9020,2 persons). Ischemic heart disease had the largest share in the structure of the studied diseases (62,25 %). There was also a decrease in life expectancy over the past 30 years and an increase in mortality of young and middle-aged people

Antenna size dependent exciton dynamics in the chlorosomal antenna of the green bacterium Chloroflexus aurantiacus

AbstractUsing picosecond fluorescence spectroscopy, we demonstrated antenna size dependent exciton dynamics in chlorosomal antenna, measured for intact cells of different cultures of the green bacterium Chloroflexus aurantiacus with different chlorosomal antenna size determined by electron microscopic examination of ultrathin sections of the cells. The measured bacteriochlorophyll (BChl) c excitation lifetimes show a quasilinear dependence on chlorosome size as predicted in our model for cylindrical exciton migration within the three-dimensional chlorosomal antenna. The migration model was developed for the proposed exciton model of chlorosomal BChl c aggregation. The data predict the time constant values for excitation energy transfer between BChl c aggregates as well as to BChl a of the baseplate

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Abstract Background The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations. Methods A total of 197 juvenile patients were enrolled in this study. Response to therapy was assessed using the ACRPedi 30/50/70/90 criteria, the Wallace criteria, and the Juvenile Arthritis Disease Activity Score 71 (JADAS-71). Univariate and multivariate logistic regression analyses were performed to identify potential baseline factors associated with treatment response in different JIA categories. Results One year after treatment initiation, 179 (90.9%) patients achieved ACRPedi30; 177 (89.8%) patients achieved ACRPedi50; 168 (85.3%) patients achieved ACRPedi70; and 135 (68.5%) patients achieved ACRPedi90 response. A total of 132 (67.0%) and 92 (46.7%) patients achieved inactive disease according to the Wallace criteria and the JADAS-71 cut-off point, respectively. Excellent response (achieving ACRPedi90 and clinically inactive disease according both to the Wallace criteria and the JADAS71 cut-off point) was associated with persistent oligoarticular JIA category, shorter disease duration before the start of etanercept, a lower number of DMARDs used before the introduction of etanercept, a lower number of joints with limited motion, and lower C-reactive protein at baseline. Poor response (failure to achieve ACR 70 or active disease according to both the Wallace criteria and JADAS71 even when ACR 70 was achieved) was associated with the polyarticular or enthesitis-related JIA categories, higher disease duration before the start of etanercept, and older age at disease onset. Conclusion Almost half (45.7%) of the patients who initiated etanercept treatment achieved an excellent response (inactive disease and ACRPedi90) after 1 year. What may be novel is our finding that the response to etanercept therapy was strongly associated with the JIA category. The response to etanercept therapy was also associated with the disease duration before the start of etanercept treatment